These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9191528)

  • 21. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    Long HJ; Bundy BN; Grendys EC; Benda JA; McMeekin DS; Sorosky J; Miller DS; Eaton LA; Fiorica JV;
    J Clin Oncol; 2005 Jul; 23(21):4626-33. PubMed ID: 15911865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
    J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vinorelbine and cisplatin for the treatment of recurrent and/or metastatic carcinoma of the uterine cervix.
    Gebbia V; Caruso M; Testa A; Mauceri G; Borsellino N; Chiarenza M; Pizzardi N; Palmeri S
    Oncology; 2002; 63(1):31-7. PubMed ID: 12187068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
    Dimopoulos MA; Papadimitriou CA; Sarris K; Aravantinos G; Kalofonos C; Gika D; Gourgoulis GM; Efstathiou E; Skarlos D; Bafaloukos D
    Gynecol Oncol; 2002 Jun; 85(3):476-82. PubMed ID: 12051877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.
    Inoue T; Obara T; Saito M; Kumazawa T; Yuasa T; Matuura S; Tsuchiya N; Satoh S; Habuchi T
    Hinyokika Kiyo; 2007 Sep; 53(9):613-8. PubMed ID: 17933135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix.
    Pohlmann P; DiLeone LP; Cancella AI; Caldas AP; Dal Lago L; Campos O; Monego E; Rivoire W; Schwartsmann G
    Am J Clin Oncol; 2002 Oct; 25(5):496-501. PubMed ID: 12393992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective chemotherapy for advanced carcinoma of the cervix with bleomycin, cisplatin, vincristine, and methotrexate.
    Rosenthal CJ; Khulpateea N; Boyce J; Mehrotra S; Tamarin S
    Cancer; 1983 Dec; 52(11):2025-30. PubMed ID: 6194875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
    Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of cisplatin and vinorelbine as first-line chemotherapy in patients with carcinoma of the uterine cervix.
    Pignata S; Silvestro G; Ferrari E; Selvaggi L; Perrone F; Maffeo A; Frezza P; Di Vagno G; Casella G; Ricchi P; Cormio G; Gallo C; Iodice F; Romeo F; Fiorentino R; Fortuna G; Tramontana S
    J Clin Oncol; 1999 Mar; 17(3):756-60. PubMed ID: 10071263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vinorelbine and cisplatin in advanced squamous cell carcinoma of the cervix: the South African experience.
    Goedhals L; Falkson G; Smith BL; Falkson CI; Gasmi J; Lategan A; Burillon JP; His P
    Anticancer Res; 2005; 25(3c):2489-92. PubMed ID: 16080481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doxorubicin-cisplatin-vinblastine combination chemotherapy of advanced endometrial carcinoma: a Southwest Oncology Group Study.
    Alberts DS; Mason NL; O'Toole RV; Hilgers RD; Rivkin SE; Boutselis JG; Pugh RP; Vaitkevicius VK; Green JB; Oishi N
    Gynecol Oncol; 1987 Feb; 26(2):193-201. PubMed ID: 3542743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.
    Necchi A; Mariani L; Giannatempo P; Raggi D; Farè E; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Maffezzini M; Pizzocaro G; De Braud FG; Gianni AM; Salvioni R
    Clin Genitourin Cancer; 2014 Jun; 12(3):203-209.e1. PubMed ID: 24394493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma.
    Morrell LE; Lee YJ; Hurley J; Arias M; Mies C; Richman SP; Fernandez H; Donofrio KA; Raub WA; Cassileth PA
    Cancer; 1998 Feb; 82(3):503-11. PubMed ID: 9452268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
    Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I/II study of vinorelbine, doxorubicin, and methotrexate with leucovorin rescue as first-line treatment for metastatic breast cancer.
    Subramanyan S; Abeloff MD; Bond SE; Davidson NE; Fetting JH; Gordon GB; Kennedy MJ
    Cancer Chemother Pharmacol; 1999; 43(6):497-502. PubMed ID: 10321510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of small cell carcinoma of the cervix with cisplatin, doxorubicin, and etoposide.
    Morris M; Gershenson DM; Eifel P; Silva EG; Mitchell MF; Burke TW; Wharton JT
    Gynecol Oncol; 1992 Oct; 47(1):62-5. PubMed ID: 1330847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cis-platinum, doxorubicin, and methotrexate treatment for recurrent cervical cancer.
    Wheelock JB; Krebs HB; Goplerud DR; Myers M
    Obstet Gynecol; 1985 Sep; 66(3):410-2. PubMed ID: 4040622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of carboplatin and cisplatin in advanced or recurrent squamous carcinoma of the uterine cervix.
    Morris M; Gershenson DM; Burke TW; Mitchell MF; Levenback C; Atkinson N; Wharton JT
    Gynecol Oncol; 1994 May; 53(2):234-8. PubMed ID: 8188085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.